Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

You can notice signs of HIV on the tongue during the early and late stages of the infection with the virus. An acute HIV ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

Lenacapavir is available in both oral tablet form and as subcutaneous injections. It is available as oral tablets and ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

In the ongoing fight against HIV, scientists have taken a new step toward long-term control of the virus. Researchers have ...

News and Analysis Published: June 2009 Tapping into combination pills for HIV Bethan Hughes Nature Reviews Drug Discovery 8, 439–440 (2009) Cite this article ...

A small French biotech is trumpeting results from a trial suggesting its developmental drug could be used as part of an HIV cure. The phase 2a trial of AbiVax’s ABX464 pill is small but confirms ...